May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Hydrophobic Biodegradable Polysaccharide Devices for Controlled Drug Delivery
Author Affiliations & Notes
  • J. Missling
    SurModics, Eden Prairie, Minnesota
  • S. Varner
    SurModics, Irvine, California
  • S. Chudzik
    SurModics, Eden Prairie, Minnesota
  • Footnotes
    Commercial Relationships J. Missling, SurModics, E; S. Varner, SurModics, E; S. Chudzik, SurModics, E.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5820. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Missling, S. Varner, S. Chudzik; Hydrophobic Biodegradable Polysaccharide Devices for Controlled Drug Delivery. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5820.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Evaluate a hydrophobic biodegradable polysaccharide device capable of delivering pharmaceutical agents in a controlled manner in an in vitro model.


Biodegradable devices comprised of a hydrophobically modified polysaccharide (h-PS), 40-50% w/w; polyethylene glycol (PEG), 20 kD average molecular weight, 0-10%; and triamcinolone acetonide (TA), 50% w/w; were fabricated by a solventless extrusion process. Materials were fed in dry powder or pellet form to an extruder which uniformly mixed the components at a temperature sufficient to melt the polymeric materials but not the TA. The resulting mixture was forced through a heated die and elongated into a 500 micrometer diameter cylindrical shape. The cooled extrudate was cut to 5 millimeter lengths to form devices with a total mass of 1 mg.Elution of the TA was determined by repeated exchanges of 4 ml phosphate buffered saline, pH 7.4, agitated and maintained at 37oC, at appropriate time intervals. Concentration of TA at each time point was quantified by UV-vis spectroscopy. Content and purity of TA in devices was determined by extracting TA with tetrahydrofuran and assaying via HPLC. Solid form of TA was confirmed by X-ray powder diffraction.


Tunability of TA elution rate from 0.1 to 5.0 µg/day was demonstrated by varying device formulation. See Figure 1. 95-105% of the TA was recovered from assayed devices and the impurities profile was unchanged. Crystalline polymorphic form of the TA was not altered. Devices were implanted into cadaveric porcine eyes via a minimally invasive technique, and were found to have appropriate mechanical integrity.


A device has been developed that provides controlled release of TA. Extrapolation of elution data predicts release will last longer than 1 year in some cases. The device may be fabricated into a shape and size suitable for minimally invasive implantation into the vitreous space.  

Keywords: vitreous • corticosteroids • injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.